(PRWEB) July 23, 2013
In the United States, there is a continued problem facing the medical community of patients with increasingly high and difficult to treat conditions such as High Cholesterol. Historically medications with statin-blockers have been given to patients with this disease in order to manage, and decrease the amounts of LDL (or bad cholesterol) in their bodies.
The race for new, and improved medications to help treat this problem is in full swing within the medical research community. One promising development are drugs which contain an antibody to PCSK9 inhibitors. These inhibitors have been tested as impairing the liver’s ability to efficiently filter out bad cholesterol from the blood.
As of this Sunday, drug maker Amgen announced that its experimental form of PCSK9 inhibitors, known as AMG-145, revealed positive results after a first trial of testing. This is the first sign of progress as its competitors are said to have their own versions currently in trial testing as well.
When asked about the developments, James McKenney, the lead study author of the trials said,
“The feeling I had when I saw the results was the feeling I had when we were studying statins in our research center… it’s important to note that these are early trial results that need to be studied in much larger populations, for longer durations.”
Upon the release of any drug such as AMG-145, the medical community is on pace to revolutionize the way this disease, and possible others, are treated in the long term.
For more updates on this story follow CNN Health, http://www.cnn.com/HEALTH/.